Effect of QSKL on MAPK and RhoA Pathways in a Rat Model of Heart Failure

Abstract EN

Qishenkeli (QSKL) is one of the Chinese medicine formulae for treating heart failure and has been shown to have an antifibrotic effect.

However, the mechanism of its therapeutic effects remains unclear.

In this study, we aimed to explore whether QSKL could exert an antifibrotic effect by attenuating ras homolog family member A (RhoA) and mitogen activated protein kinase (MAPK) pathways.

Rats were randomly divided into sham group, model group, QSKL group, and positive control group.

Heart failure was induced by ligation of the left ventricle anterior descending artery.

Cardiac functions were measured by echocardiography and collagen deposition was assessed by Masson staining.

Expressions of the key molecules involved in the RhoA and MAPK pathways were also measured.

Twenty-one days after surgery, cardiac functions were severely impaired and collagen deposition was remarkable, while QSKL treatment could improve heart functions and alleviate collagen deposition.

Further results demonstrated that the effects may be mediated by suppressing expressions of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK).

Moreover, expressions of RhoA, Rho-associated protein kinase 1/2 (ROCK1/2), and phosphorylated myosin light chain (p-MLC) were also downregulated by QSKL compared with the model group.

The cardioprotective mechanism of QSKL on heart failure is probably mediated by regulating both the MAPK and RhoA signaling pathways.